Sangamo Biosciences reported $-45881000 in EBITDA for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acceleron Pharma XLRN:US $ -69.47M 6.84M
Alnylam Pharmaceuticals ALNY:US $ -169.89M 35.54M
Amgen AMGN:US $ 3228M 40M
Avrobio Inc AVRO:US $ -32246000 1.17M
Bayer BAYN:GR € 2089M 946M
Biogen BIIB:US $ 991.8M 155.8M
Biomarin Pharmaceutical BMRN:US $ -9.16M 48.05M
Bluebird Bio BLUE:US $ -190.8M 44.05M
Gilead Sciences GILD:US $ 4370M 1605M
GlaxoSmithKline GSK:LN 3660M 1034M
Intercept Pharmaceuticals ICPT:US $ -5.41M 6.8M
Johnson & Johnson JNJ:US $ 8192M 2043M
Karyopharm Therapeutics KPTI:US $ -43626000 5.19M
Novartis NOVN:VX SF 4837M 65M
Omeros OMER:US $ -17936000 5.72M
Pfizer PFE:US $ 10235M 2245M
Sangamo Biosciences SGMO:US $ -45.88M 0.57M
Sarepta Therapeutics SRPT:US $ -23.96M 135.16M
Ultragenyx Pharmaceutical RARE:US $ -86.61M 6.96M
Vertex Pharmaceuticals VRTX:US $ 1087.41M 1092.53M